BCIRG-006

NCT00021255 📎

Regimen

Experimental
TCH (docetaxel + carboplatin + trastuzumab x 6) or AC-TH (doxorubicin/cyclophosphamide then docetaxel + trastuzumab), with trastuzumab continued for 1 year.
Control
AC-T (doxorubicin/cyclophosphamide then docetaxel, no trastuzumab).

Population

HER2-positive early breast cancer, node-positive or high-risk node-negative, suitable for adjuvant chemotherapy.

Key finding

BCIRG-006 validated anthracycline-free TCH as a non-inferior, less cardiotoxic alternative to AC-TH. NCCN includes TCH as preferred regimen for patients with cardiac risk. 10-year follow-up confirmed OS benefit and safety advantage of TCH.

Source: PMID 21991949

Timeline

  • Publication: 2011 Oct 6

Guideline citations

  • NCCN BREAST